Lameditech

At a glance

Lameditech filed 18 disclosures in the last 12 months, including 1 5% holder and 1 issuance. The most recent key filing was on Jun 24.

Revenue for 2025 was ₩7.2B, up 9.3% on 2024. It made an operating loss of ₩11.8B. Debt was 199% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩1.9B and operating loss of ₩4.5B.

The 2025 annual report lists 68 employees with an average tenure of 2 years and average pay of ₩54.6M, #1240 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩145.2M each on average. It paid no cash dividend for 2025. 최종석 and related parties held 29.51% at year end.

From the 2025 annual report

Staff: 68 (47 men, 21 women), of whom 6 on fixed-term contracts. Total pay for the year: ₩3.7B. Directors and auditors: 8, paid ₩1.2B in total.

No cash dividend was paid for 2025.

Largest shareholder

최종석 holds 24.82%; with 4 related parties the group holds 29.51% of common shares at year end (from 28.85% at the start of the year).

Auditor: 태성회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary